RIVA-OXYBUTYNIN 5 MG
OXYBUTYNIN CHLORIDE : 5 MG · DIN 02299364 · LABORATOIRE RIVA INC.
Health Canada status: DORMANT
What is RIVA-OXYBUTYNIN?
RIVA-OXYBUTYNIN 5 MG contains OXYBUTYNIN CHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02299364, held by LABORATOIRE RIVA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 24-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIVA-OXYBUTYNIN used for?
Relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflex neurogenic bladder (urgency, frequency, urinary leakage, urge incontinence, dysuria).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02299364 |
|---|---|
| Brand name | RIVA-OXYBUTYNIN |
| Generic / active ingredient | OXYBUTYNIN CHLORIDE : 5 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD04 OXYBUTYNIN |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 24-Jul-2026 |
| Original market date | 2008-03-17 00:00:00 |
How is it administered?
Adults: 5 mg 2-3 times/day (max 4 times/day). Children >5: 5 mg 2 times/day (max 3 times/day). Elderly: Start at lowest dose and increase carefully.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30°C in tight container. Protect from light.
How is it supplied?
HDPE bottles of 100 and 500 tablets.
Contraindications
Glaucoma, GI obstruction, paralytic ileus, intestinal atony, megacolon, severe colitis, myasthenia gravis, obstructive uropathy, unstable cardiovascular status in acute hemorrhage, hypersensitivity.
Warnings and precautions
Can cause heat prostration in high temperatures. May cause drowsiness or blurred vision; caution with machinery/driving. Diarrhea may signal incomplete intestinal obstruction.
Is OXYBUTYNIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Discontinued — reported by SANIS HEALTH INC, last seen 04 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code G04BD04 OXYBUTYNIN. 5 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXYBUTYNIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02163543 |
| PMS-OXYBUTYNIN | 2.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02240549 |
| PMS-OXYBUTYNIN | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02240550 |
| PMS-OXYBUTYNIN | 5 MG / 5 ML | SYRUP | PHARMASCIENCE INC | MARKETED | DIN 02223376 |
| TEVA-OXYBUTYNIN | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02230394 |
| ALBERT OXYBUTYNIN | 5 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02220067 |
| APO-OXYBUTYNIN | 1 MG | SYRUP | APOTEX INC | DORMANT | DIN 02231089 |
| AVA-OXYBUTYNIN | 5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363917 |
| DITROPAN SYRUP 1MG/ML | 1 MG | SYRUP | JANSSEN INC | CANCELLED POST MARKET | DIN 01924753 |
| DITROPAN TABLETS 5MG | 5 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 01924761 |
Who else supplies OXYBUTYNIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXYBUTYNIN appears in 39 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.